DNA saturation mutagenesis: Identifying which mutations really cause disease

15-Aug-2019 - Scientists at the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin, working with colleagues from the United States, have selectively modified the control regions of 20 disease-relevant genes. This enabled them to identify precisely those modifications that have the ...

DxS Expands in US with Appointment of Jane Papadaki-Markley as Sales and Marketing Director for North America

19-Jan-2009 - DxS Ltd has announced the appointment of Jane Papadaki-Markley as Sales and Marketing Director as it expands in North America. Jane is based in California and will be responsible for the continued expansion of DxS’ tumour mutation analysis products in the US and Canada. Jane joins DxS from ...

Gene elevating breast cancer risk also causes prostate cancer

13-Feb-2007 - An international multi-centre research effort, including Karolinska Institutet, has identified a new genetic defect as a potential heritable breast cancer susceptibility candidate. To some extent, prostate cancer also seems to be caused by the discovered PALB2 mutation. The two major familial ...

DxS receives Biotechnology Award for Cancer product from BioNow

30-Nov-2006 - DxS has won a 'Biotechnology Project of the Year' award for its highly sensitive EGFR (Epidermal Growth Factor Receptor) Mutation Test Kit. Sponsored by the Manchester based law firm Pannone LLP, the award was presented by Bionow, the Northwest Regional Development Agency's (NWDA) biotechnology ...

Genzyme Launches New Diagnostic Test for Common Blood Cancer

p53 Mutation Analysis Offers Critical Prognostic and Predictive Information for B-Cell Chronic Lymphocytic Leukemia

31-Jul-2006 - Genzyme Corporation announced the availability of its p53 Mutation Analysis for B-cell chronic lymphocytic leukemia (B-CLL). P53 is a tumor suppressor gene that stops cell division when DNA damage is present. When the p53 gene does not function normally, genetic mutations that can occur in ...

Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia

Tools Improve Treatment Management of AML Patients

19-May-2006 - Genzyme Corporation announced the availability of two new molecular tests for acute myelogenous leukemia (AML) with the launch of FLT3 Mutation Analysis and WT1 RQ-PCR. FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies. The WT1 RQ PCR ...

Genzyme Launches Key Test To Monitor Gleevec Resistance

Two Additional Personalized Medicine Tests Also Available

13-Feb-2006 - Genzyme Corporation announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately four to five percent of patients who were ...

Tm Bioscience reports Genzyme Genetics launch of upgraded cystic fibrosis test

19-Sep-2005 - Tm Bioscience Corporation announced that Genzyme Genetics launched its upgraded CFplus(TM) cystic fibrosis (CF) mutation analysis which now includes testing for 97 mutations. Genzyme Genetics' new CFplus(TM) assay incorporates technology from Tm Bioscience which was developed in a collaborative ...